Satoshi Shinohara, Rei Sunami, Genki Yasuda, Mayuko Kasai
{"title":"sFlt-1/PlGF比值预测早发型胎儿生长受限的严重后果。","authors":"Satoshi Shinohara, Rei Sunami, Genki Yasuda, Mayuko Kasai","doi":"10.1159/000547695","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to identify a cutoff value for the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio to predict adverse outcomes in early-onset fetal growth restriction (FGR).</p><p><strong>Methods: </strong>In this single-center, non-blinded, retrospective cohort study, maternal serum sFlt-1/PlGF ratios were measured at the time of early-onset FGR diagnosis (<34 weeks) using Roche Elecsys® assays. The optimal cutoff for predicting severe adverse outcomes within 2 weeks was determined using receiver operating characteristic analysis. The Kaplan-Meier analysis assessed delivery probability, and Cox proportional hazards models evaluated factors associated with pregnancy continuation.</p><p><strong>Results: </strong>Among 332 patients, 61 (18.4%) delivered within 2 weeks due to worsening FGR. An sFlt-1/PlGF ratio ≥99.0 predicted adverse outcomes leading to an inability to continue the pregnancy, with 85.3% sensitivity and 91.5% specificity (area under the curve: 0.92). Women with ratios ≥99.0 had a significantly shorter time to delivery (p < 0.001). The ratio remained a significant predictor of adverse outcomes in both asymptomatic and preeclampsia-complicated FGR.</p><p><strong>Conclusion: </strong>The sFlt-1/PlGF ratio is a strong predictor of short-term adverse outcomes in early-onset FGR, aiding in risk stratification and clinical decision-making.</p>","PeriodicalId":12189,"journal":{"name":"Fetal Diagnosis and Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"sFlt-1/PlGF Ratio Predicts Serious Outcomes in Early-Onset Fetal Growth Restriction.\",\"authors\":\"Satoshi Shinohara, Rei Sunami, Genki Yasuda, Mayuko Kasai\",\"doi\":\"10.1159/000547695\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This study aimed to identify a cutoff value for the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio to predict adverse outcomes in early-onset fetal growth restriction (FGR).</p><p><strong>Methods: </strong>In this single-center, non-blinded, retrospective cohort study, maternal serum sFlt-1/PlGF ratios were measured at the time of early-onset FGR diagnosis (<34 weeks) using Roche Elecsys® assays. The optimal cutoff for predicting severe adverse outcomes within 2 weeks was determined using receiver operating characteristic analysis. The Kaplan-Meier analysis assessed delivery probability, and Cox proportional hazards models evaluated factors associated with pregnancy continuation.</p><p><strong>Results: </strong>Among 332 patients, 61 (18.4%) delivered within 2 weeks due to worsening FGR. An sFlt-1/PlGF ratio ≥99.0 predicted adverse outcomes leading to an inability to continue the pregnancy, with 85.3% sensitivity and 91.5% specificity (area under the curve: 0.92). Women with ratios ≥99.0 had a significantly shorter time to delivery (p < 0.001). The ratio remained a significant predictor of adverse outcomes in both asymptomatic and preeclampsia-complicated FGR.</p><p><strong>Conclusion: </strong>The sFlt-1/PlGF ratio is a strong predictor of short-term adverse outcomes in early-onset FGR, aiding in risk stratification and clinical decision-making.</p>\",\"PeriodicalId\":12189,\"journal\":{\"name\":\"Fetal Diagnosis and Therapy\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fetal Diagnosis and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547695\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fetal Diagnosis and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547695","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
sFlt-1/PlGF Ratio Predicts Serious Outcomes in Early-Onset Fetal Growth Restriction.
Introduction: This study aimed to identify a cutoff value for the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio to predict adverse outcomes in early-onset fetal growth restriction (FGR).
Methods: In this single-center, non-blinded, retrospective cohort study, maternal serum sFlt-1/PlGF ratios were measured at the time of early-onset FGR diagnosis (<34 weeks) using Roche Elecsys® assays. The optimal cutoff for predicting severe adverse outcomes within 2 weeks was determined using receiver operating characteristic analysis. The Kaplan-Meier analysis assessed delivery probability, and Cox proportional hazards models evaluated factors associated with pregnancy continuation.
Results: Among 332 patients, 61 (18.4%) delivered within 2 weeks due to worsening FGR. An sFlt-1/PlGF ratio ≥99.0 predicted adverse outcomes leading to an inability to continue the pregnancy, with 85.3% sensitivity and 91.5% specificity (area under the curve: 0.92). Women with ratios ≥99.0 had a significantly shorter time to delivery (p < 0.001). The ratio remained a significant predictor of adverse outcomes in both asymptomatic and preeclampsia-complicated FGR.
Conclusion: The sFlt-1/PlGF ratio is a strong predictor of short-term adverse outcomes in early-onset FGR, aiding in risk stratification and clinical decision-making.
期刊介绍:
The first journal to focus on the fetus as a patient, ''Fetal Diagnosis and Therapy'' provides a wide range of biomedical specialists with a single source of reports encompassing the common discipline of fetal medicine.